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This study aimed at quantitatively comparing the occur-
rence/formation of DNA adducts with the carcinogenicity
induced by a selection of DNA-reactive genotoxic carci-
nogens. Contrary to previous efforts, we used a very
uniform set of data, limited to in vivo rat liver studies in
order to investigate whether a correlation can be obtained,
using a benchmark dose (BMD) approach. Dose–response
data on both carcinogenicity and in vivo DNA adduct
formation were available for six compounds, i.e. 2-
acetylaminofluorene, aflatoxin B1, methyleugenol, safrole,
2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline and ta-
moxifen. BMD10 values for liver carcinogenicity were
calculated using the US Environmental Protection Agency
BMD software. DNA adduct levels at this dose were
extrapolated assuming linearity of the DNA adduct dose
response. In addition, the levels of DNA adducts at the
BMD10 were compared to available data on endogenous
background DNA damage in the target organ. Although
for an individual carcinogen the tumour response increases
when adduct levels increase, our results demonstrate that
when comparing different carcinogens, no quantitative
correlation exists between the level of DNA adduct
formation and carcinogenicity. These data confirm that
the quantity of DNA adducts formed by a DNA-reactive
compound is not a carcinogenicity predictor but that other
factors such as type of adduct and mutagenic potential may
be equally relevant. Moreover, comparison to background
DNA damage supports the notion that the mere occurrence
of DNA adducts above or below the level of endogenous
DNA damage is neither correlated to development of
cancer. These data strongly emphasise the need to apply
the mode of action framework to understand the contri-
bution of other biological effect markers playing a role in
carcinogenicity.
Introduction
Cancer induced by exogenous as well as endogenous sources
of chemicals acting through genotoxic mechanisms is a multi-
step process, which needs a number of critical events before the
adverse effect is developed (1). Briefly, it involves an initiation
step damaging the DNA and/or forming DNA adducts,
followed by at least one round of DNA synthesis to fix the
genetic damage. The promotion stage which is a reversible step
is characterised by genetic instability and clonal expansion (2)
stimulating the induction of cell proliferation, resulting in the
formation of an identifiable focal lesion. Progression, consid-
ered an irreversible process, is the final step characterised by
accumulation of additional genetic damage and cell pro-
liferation. Formation of endogenously damaged DNA bases
has been measured and quantified in various experimental
studies. This damage has been reported to result from damage
induced by oxidative stress, with reactive oxygen species being
a major source for formation of damaged DNA bases (3).
Furthermore, DNA damage may result from adduct formation
by endogenous alkylating electrophiles, such as by-products
resulting from lipid peroxidation (3). In addition to these
endogenous factors, an important factor contributing to the
occurrence of DNA damage can be found in exposure to
exogenous DNA-reactive carcinogens. DNA adduct formation,
although involved in the process of cancer formation, is
generally considered a biomarker of exposure (4–6) rather than
a biomarker of effect although it is also well recognised that
increased levels of DNA adduct formation reflect a risk factor
for cancer development. Progress has been made in un-
derstanding the mode of action (MOA) of DNA-reactive
carcinogens but still not all pathways are clearly defined. The
formation of DNA adducts is considered a prerequisite of
cancer induction by DNA-reactive genotoxic carcinogens,
which, with or without metabolic conversion to a reactive
metabolite can react with DNA to form adducts resulting in
mutation and eventually carcinogenic transformation (7).
Several attempts have been made to correlate the occurrence
of DNA adducts with the carcinogenic outcome, but the
significance of their formation in the risk assessment,
especially with respect to the discussion and justification of
possible thresholds is a matter of ongoing debate (8,9).
As reported by Boobis et al. (10), there are several critical
key events in the MOA of DNA-reactive carcinogens:
(i) exposure of the target cells to the ultimate reactive and
mutagenic species, (ii) reaction with DNA in the target cells,
(iii) misreplication or misrepair of the lesion and (iv) mutations
in critical genes in replicating target cells, etc. (clonal
expansion, further mutations, uncontrolled growth, progres-
sion, malignancy). DNA-reactive carcinogens, directly or upon
metabolic activation, can covalently bind to cellular DNA.
DNA adducts occur at nucleophilic sites in the DNA strands
(5), and this process can result in the formation of different
types of adducts (5). DNA adduct formation can be a reversible
process since living organisms contain DNA repair mecha-
nisms that are able to repair DNA damage induced by
endogenous and exogenous electrophiles. These DNA repair
mechanisms are supported by 130 genes involved in different
distinct repair processes (11), including for example, direct
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repair, mismatch repair, base excision repair, nucleotide
excision repair and homologous recombination repair (11–
13). If not repaired, DNA lesions can be misread by DNA
polymerases, leading to heritable mutations (5). While DNA
adducts are a biomarker of exposure (4–6), mutations are
considered biomarkers of effect (6). In an attempt to fill the gap
between DNA adduct formation as a biomarker of exposure
and tumour incidences as a biomarker of effect, the aim of the
present paper was to make a quantitative comparison between
data on in vivo DNA adduct formation and on tumour
incidences taking into account reported endogenous back-
ground levels of DNA adduct formation.
Methodology
Compound selection
DNA-reactive carcinogens included in the present study were
selected based on the following criteria: (i) available data on in
vivo DNA adduct formation and (ii) available dose–response
data for tumour induction, both in the same target tissue, the
liver, for the same species, the rat, and for the same gender,
after oral administration (by gavage, feed or water). Data were
searched using the ISI Web of Science (14), PubMed (15), the
Carcinogenic Potency Database (CPDB) (16–18) and the
database of the US National Toxicology Program (19).
Benchmark dose software
The tumour incidence data obtained were modelled with the
benchmark dose (BMD) software version 2.1.1 developed by
the US Environmental Protection Agency (EPA) (20). The
BMD methodology was developed by Crump (21) and is based
on statistically fitting a dose–response model to experimental
data. The advantage of applying the BMD software in
analysing tumour incidence data is that all information of the
dose–response curve is taken into account (20–22). The BMD
level thus defined is not limited to an experimental dose level
and is defined as the dose producing a defined change in
response, for example 10% response, above background level
defined as the Benchmark Response (BMR) 10%. The
parameters for the computer modelling, using dichotomous
models, were set as default predefined in the EPA software:
95% confidence limit, extra risk and the BMR value set at 0.1.
The BMD10 values were expressed as milligrams per kilogram
body weight per day for each mathematical model. The
following dichotomous models were selected: gamma, logistic,
log-logistic, log-probit, multistage, probit, quantal-linear and
Weibull. These models are each represented by a specific
mathematical equation (20–22). Models were accepted or
rejected based on the log-likelihood. The log-likelihood ratio
test is based on the log-likelihood value associated with a fitted
model compared with, and tested against, the log-likelihood
value associated with the so-called ‘full model’ (20–22). The
full model simply consists of the observed (mean) responses at
each applied dose (19,20). Hence, the number of parameters
equals the number of dose groups. If a model fit is not
significantly worse than that of the full model, then the model
may be accepted (20–22). Furthermore, an extra criteria for
accepting or rejecting the models was the P-value. When the P-
value was .0.1, the models were accepted (20–22), and only
those BMD10 values were further used to estimate DNA adduct
levels. In the case that several models provide an adequate fit to
a given data set, the goodness-of-fit was further evaluated on
the basis of the Akaike Information Criterion (AIC) value. The
AIC is a deviant of the log-likelihood and penalises a model for
having too many parameters (i.e. degrees of freedom), thus
allowing to compare the goodness-of-fit between different
models. Lower AIC values indicate a better fit within a data set
(20–22).
Aspects related to 32P-postlabelling
In order to use data set as uniform as possible, experimental
studies using similar analytical methods for detection and
quantification were applied. For four carcinogens, data on total
DNA adduct levels were available, generated using 32P-
postlabelling followed by thin layer chromatography (TLC)
separation; for methyleugenol (ME), the separation step was
not specified. The types of adduct(s) formed were in most cases
not characterised. 32P-postlabelling is a highly sensitive
method which needs only small amounts of DNA (23,24)
and it has been the most widely used method for the detection
of DNA adducts. However, a limitation of the 32P-postlabelling
method is the potential for underestimation of the adduct levels
due to incomplete DNA digestion, submaximal efficiency of
adduct labelling by polynucleotide kinase and/or loss of
adducts during enrichment and chromatography stages (25).
For aflatoxin B1 (AfB1), available data were generated using
3H-HPLC, the N-7 guanine is the predominant adduct formed
by AfB1, which is poorly labelled by 32P-postlabelling
technique (25).
Dose adjustment for cancer bioassays
In order to correct the doses and the duration of treatment to the
standard lifespan (2 years or 104 weeks by convention), we
followed the recommendations of Peto et al. (26) and Gold
et al. (27). Two principal situations of dose adjustments exist:
in the first situation, administration of the test compound is
discontinued before the terminal sacrifice after completion of
the full duration of 2 years. In this case, the dose is adjusted by
multiplying with f 5 (period of active treatment)/(actual time
on test, i.e. 104 weeks). This was the case for the highest dose
group in the ME study, which was stopped after 53 weeks due
to toxic side effects and continued to 104 weeks without
treatment (26). This dose was, therefore, adjusted by f 5
(53/104). In the second principal situation, both the treatment
and the study are terminated before completion of the standard
lifespan, e.g. after 52 weeks. In this case, the f2 correction
factor is used where f 5 (experiment time)/(standard lifespan).
This was the case for the AfB1 study, where all except the
lowest dose groups were terminated ‘prematurely’ between 54
and 93 weeks due to mortality (26,28). For the ‘mixed’
situation, where the study is terminated before completion of
the 104 weeks, and treatment is even shorter, the adjustment
was done by correcting for [(period of active treatment)/
(standard lifespan)]  [(experiment time)/(standard lifespan)].
Thus, in cases where treatment time equals study duration this
corresponds exactly to the f2 approach.
When dosing was done during only 5 days of the week, as
was the case for ME, the dose was corrected by f 5 5/7.
Results
Compound selection
DNA-reactive carcinogens in the present study were selected
based on (i) available data on in vivo DNA adduct formation
and (ii) available dose–response data for tumour induction,
both in the same target tissue, the liver, for the same species,
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the rat, and for the same gender. In vivo DNA adduct formation
data were available for a large number of carcinogens.
However, the number of in vivo studies on tumour formation
in the same species, sex and target tissue for which data also on
in vivo DNA adduct formation were available, were limited.
Only six DNA-reactive carcinogens were identified for which
data on both tumour incidence and in vivo DNA adduct
formation in rat liver were available. The compounds selected
were: 2-acetylaminofluorene (2-AAF) (CAS # 53-96-3); AfB1
(CAS # 1162-65-8); ME (CAS # 93-15-2); safrole (SA) (CAS
# 94-59-7); 2-amino-3,8-methylimidazo[4,5-f]quinoxaline
(MeIQx) (CAS # 77500-04-0) and tamoxifen (TAM) (CAS #
54965-24-1). Even though the compounds were selected as to
obtain relatively uniform data set regarding target tissue,
species and gender, important variations were observed in the
available information with respect to study design, such as
duration (5 days up to 18 months), dosing (water, diet, gavage),
group size (2) and analytical methods employed. This is
especially relevant concerning the DNA adduct data, for which
(in contrast to, e.g. a 2 years cancer bioassay), no guideline
study protocols exist.
Data on in vivo DNA adduct formation
Table I recapitulates the data collected for the dose dependent
in vivo DNA adduct formation of the selected DNA-reactive
carcinogens (2-AAF, AfB1, ME, SA, MeIQx and TAM)
focussing on liver as the target organ. All data sets collected for
the individual carcinogens were from rats, with the data for five
of the six carcinogens being obtained in male rat liver, whereas
those for TAM were obtained in female rat liver. Table I
presents information on the data collected including informa-
tion on dose in milligrams per kilogram body weight per day,
exposure route and duration, amount of DNA adducts formed,
type of adduct detected, method of analysis, species and
gender. Exposure duration, dose ranges applied and mode of
administration appear to vary between the studies available for
the different model compounds. For instance, study duration
varies from as short as 5 days (SA) up to 18 months of
exposure (TAM). Due to the paucity of available data on
formation kinetics, DNA adduct levels were assumed to have
reached near steady state and were used as such without any
normalisation or adjustments. Therefore, data from the longest
available treatment duration were used. For SA, the longest
available treatment duration was 5 days and this may be
borderline to our selection criteria. The steady-state level of
DNA adducts are a function of dose and adduct produced in
a cell, modulated by processes linked to drug-metabolising
enzymes that activate or detoxify the genotoxic compound.
Furthermore, steady-state levels are influenced by the type of
DNA adduct and the DNA adduct half-life (36). However,
using a physiologically based kinetic (PBK) model for SA (37),
which is based on a published PBK model for the related
alkenylbenzene estragole (38,39), it can be estimated that at the
dose levels used for DNA adduct analysis by Daimon et al.
(32) of 62.5, 125 and 250 mg/kg bw/day, full conversion of SA
will be obtained in 60, 62 and 70 h, respectively. Furthermore,
Miller et al. (40) reported that the metabolite 1#-sulfooxysa-
frole has a half-life of 1 min and quickly binds to DNA.
Therefore, we conclude that the biological responses towards
SA may be rapid and may result in a steady state in DNA
adduct levels in a relatively short period of time.
To allow comparison, Table I presents all data on adduct
formation expressed as number of adducts in 108 nucleotides
(nt). A graphical representation of the dose–response curves
is shown in Figure 1 that appears to fit linear dose responses
in accordance with the current scientific view on low dose
linearity of DNA formation (6,9) (Figure 1). Therefore, and
due to the lack of data points to perform a statistical curve fit
with sufficient confidence, no non-linear curve fit was
applied to the DNA adduct dose–response data. Instead,
linear regression through the origin was applied to all data
sets without any transformation. The linear regression gave
satisfactory results for all six compounds (P , 0.005) based
on the residual plot and the P-value from the run test (P .
0.5). The data obtained allow comparison of the relative
potency of the six DNA-reactive carcinogens to form DNA
adducts. To allow such a comparison, a normalisation for
dose was applied by calculating for all six compounds the
expected levels of DNA adduct formation at a dose of 1 mg/
kg bw/day using the dose–response data plotted in Figure 1.
This results in the following decreasing order for DNA
adduct formation at a dose of 1 mg/kg bw/day: AfB1 (40480
adducts/108 nt) . 2-AAF (24002 adducts/108 nt) . MeIQx
(159 adducts/108 nt) . TAM (59 and 15 adducts/108 nt,
Table I. Published DNA adduct data, including dose, exposure route, exposure duration, number of adducts detected in the liver, adduct type, method of detection,
species and gender
Compound Daily dose (mg/kg/day) Exposure
route
Exposure
duration
Number of
adducts/108 nt
Adduct type Method Species/
gender
Reference
2-AAF 0-0.0011-0.011-0.333a Gavage 12 w*16 w 4-9-40-8000 Total adducts 32P-postlab-TLC Rat/M (29)
AfB1 2.2*10673*1062110*106 Water 8 w 0.091-3.2-85 Aflatoxin-DNA adducts 3H/HPLC Rat/M (30)
ME 1-5-50 Diet 28 d 0(ND)-1-50 Total adduct 32P-postlab Rat/M (31)
SA 0-1-10-100-250-500 Gavage 1 d 7-9-36-163-303-720 Total adduct 32P-postlab-TLC Rat/M (32)
0-62.5-125-250 Gavage 5 d 27-430-673-898 Total adduct 32P-postlab-TLC Rat/M (32)
MeIQx 0.0013-0.013-0.134-1.26b Diet 1 w 0.399-2.81-33.6-390 Total adduct 32P-postlab-TLC Rat/M (33)
0.0023-0.023-0.235-2.2c Diet 12 w 1-10-100-1000d Total adduct 32P-postlab-TLC Rat/M (33)
TAM1 0-20-40e Diet 18 m 0-300-610 Total adduct 32P-postlab-TLC Rat/F (34)
TAM2 4-20-40e Diet 8 w 225-1050-2000d Total adduct 32P-postlab-TLC Rat/F (35)
ND: not detected (,1/108 nt); M, male; F, female, d, days; w, weeks; m, months.
aConverted from cumulative doses.
bConverted from total daily doses assuming a body weight of 200 g.
cConverted from total daily doses assuming a body weight of 350 g.
dEstimated from a graph.
eConverted from 50–250 to 500 p.p.m. TAM in feed using 0.02 kg daily intake and 0.25 kg bw.
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respectively) (34,35) .SA (4 adducts/108 nt) . ME (1
adducts/108 nt). Assuming that the level of DNA adduct
formation will increase over time in a linear way, with the
number of adducts formed each day being equal to the
number formed minus the number that are lost or repaired
(6), one could further normalise the data to a 1-day exposure,
in order to be able to compare the relative potency between
compounds. The values obtained above for the total number
of adducts/108 nt at a dose of 1 mg/kg bw/day were thus
converted to numbers of adducts/108 nt/day by dividing the
total numbers by the exposure duration; resulting in the
following decreasing potency order: AfB1 (723 adducts/108
nt/day) . 2-AAF (214 adducts/108 nt/day) . MeIQx (1.89
adducts/108 nt/day) . TAM (1 adducts/108 nt/day) (35) .
SA (0.82 adducts/108 nt/day) . ME (0.035 adducts/108 nt/
day) . TAM (0.03 adducts/108 nt/day) (34). Together these
data point at a different potency for each individual
compound to result in DNA adduct formation, with AfB1
and 2-AAF being at least 2–3 orders of magnitude more
effective in forming DNA adducts than MeIQx and SA and
even 4 orders of magnitude more effective than ME and
TAM.
It should be noted that rats treated with TAM in the study by
Li et al. (34) had undergone partial hepatectomy before
treatment, which, by inducing liver proliferation, may have
influenced the levels of DNA adduct formation.
Tumour incidence data and BMD10 calculation
To allow quantitative comparison of dose levels causing DNA
adduct formation and dose levels causing a significant increase
above background levels in tumour incidence, data from long-
term studies on tumour incidence induced by the selected set of
model DNA-reactive carcinogens in rodent species were
collected from the literature. Table II presents an overview of
Fig. 1. Dose-dependent DNA adduct formation (number of adducts in 108 nt), in the liver as obtained from in vivo studies in male rats treated with: (A) 2-AAF,
(B) AfB1, (C) MeIQx, (E) SA and (F) ME and in female rats treated with (D) TAM (34,35). For all six DNA-reactive carcinogens, linearity was assumed resulting
in the following slope [(#adduct 108 nt)/(mg/kg bw/day)] factors, (m): 2-AAF, m 5 24002; AfB1, m 5 40480; ME, m 5 0.9917; SA, m 5 4.0899; MeIQx, m 5
454.22; TAM, m 5 18.24 and TAM, m 5 54.45. Inserts are log-log plots of doses and DNA adduct levels.
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in vivo hepatic tumour incidence data obtained in rats as
reported in the literature. Available tumour incidence data from
carcinogenicity studies of the six DNA-reactive compounds
(2-AAF, AfB1, ME, SA, MeIQx and TAM) are presented
including information on dose, exposure route and duration,
liver tumour incidence, type of tumour lesion and species/
gender (Table II). Exposure to the compounds was via the diet
with the exception of ME and TAM, which were dosed by
gavage. In order to use data sets as uniform as possible,
exclusively the development of hepatocellular carcinoma was
taken into consideration since this end point was separately
available for all compounds. Time of treatment was 1 year for
MeIQx and .1 year for the remaining carcinogens. All data
sets collected were for male rats with the exception of TAM for
which only female rat data were available. In a next step, all
data were modelled using the BMD software. The BMD10
values thus obtained for the six selected DNA-reactive
carcinogens, expressed in milligrams per kilogram body weight
per day, are reported in Table III. Each compound resulted in
up to nine valid BMD10 values because of the number of
models (9) used to calculate the BMD10 (Table III). The
BMDL10 values were also calculated but only the BMD10 were
used for further comparison; P-value, log-likelihood and AIC
are reported in Table III. Results obtained showed a large
variation in the BMD10 values for the six model DNA-reactive
carcinogens. For instance, the upper value of the BMD10 for
AfB1 for male rats amounted to 0.00033 mg/kg bw/day. On the
other hand, the highest BMD10 was found for male rats treated
with SA and amounted to 169.1 mg/kg bw/day. The results
from the BMD10 analysis show an increasing trend in the
BMD10 value in the order AfB1 , 2-AAF , MeIQx , TAM
, ME , SA. This order is identical to the order obtained on
the basis of the carcinogenic potency estimates expressed as the
TD50 that can be found in the CPDB (16). The TD50 is defined
as the chronic dose rate (in milligrams per kilogram body
weight per day), which would have 50% of tumour-free
animals at the end of a standard lifespan experiment time for
the species (26), or, simplified, represents the daily dose
inducing tumours in half of the test animals (above background
incidence). Based on the TD50 values, the order in the
carcinogenic potency of the six model carcinogens of the
present study was AfB1 (0.0032 mg/kg bw/day) . 2-AAF
(1.22 mg/kg bw/day) . MeIQx (1.66 mg/kg bw/day) . TAM
(3.96 mg/kg bw/day) . ME (19.7 mg/kg bw/day) . SA (441
mg/kg bw/day) and thus similar to the order defined on the
basis of the BMD10 approach in the present study, which is not
surprising since dose–response modelling and adjustments for
exposure and experimental duration are also employed to
derive the TD50 values in the CPDB (26,27). It can also be
noted that this order of potencies is roughly similar to the order
derived for their potency in inducing DNA adduct formation.
Comparison of the BMD10 data for cancer incidence to the
data on in vivo DNA adduct formation
The quantitative BMD10 values defined from the tumour
incidence data were compared to the dose–response curves for
DNA adduct formation. To illustrate this comparison, Figure 2
presents the dose–response curves for DNA adduct formation
already presented in Figure 1, but now including the range of
accepted BMD10 values obtained for each carcinogen focus-
sing on the same gender for which the DNA adduct levels were
reported. The results obtained reveal that generally the BMD10
values (Figure 2, dashed lines) fall within the in vivo
experimental dose ranges enabling detection of DNA adduct
formation. This also allowed the calculation of the number of
DNA adducts expected to occur at each BMD10, using the
linear extrapolation curves for the in vivo data for DNA adduct
formation and these values are reported in Table III. The
different data sets resulted in different models exhibiting the
best fit (Table III). Therefore, none of the models was
appropriate to model all data sets. In order to avoid averaging
across the different BMD10 values obtained with the different
models [as suggested in (28), based on (48)], accepted BMD10
values were computed and used individually in order to
extrapolate DNA adduct levels and for visualisation in
Figure 3. This approach also provided a good visual indication
of values obtained using the BMD software. It can be
concluded that at BMD10 levels for tumour induction,
significant levels of DNA adduct formation can be detected
for all six DNA-reactive carcinogens. The highest amount of
DNA adducts formed at the BMD10 was found for male rats
exposed to 2-AAF followed by male rats exposed to MeIQx .
male rats exposed to SA . male rats exposed to AfB1 . male
rats exposed to ME. The amount of DNA adducts formed at the
BMD10 for female rats exposed to TAM was comparable to the
level found for ME in male rats. The results also show that the
number of adducts covers a range of 20–11 000 adducts in 108
nt at the dose levels causing 10% increase in tumour incidence
above background levels, i.e. ,3 orders of magnitude, while
the carcinogenic potencies (based on TD50) covers .5 orders
Table II. Published tumour incidence data, including dose, exposure route, exposure duration (w 5 weeks, m 5 months), the dose adjusted to 2 years of duration
and exposure, tumour incidences in the liver, type of lesion, species and gender
Compound Dose
(mg/kg bw/day)
Exposure
route
Exposure
duration (weeks)
Time adjusted
dose (mg/kg bw/day)a
Liver tumor incidence Type of lesion
in the liver
Species/
gender
Reference
2-AAF 0-0.32-1.6-8 Diet 104 0-0.32-1.6-8 0/30-3/29-26/28-23/23 hpc Rat/M (41)
AfB1 0-0.001-0.005-
0.015-0.05-0.1
Diet 104-104-93-
96-82-54
0-0.00004-0.00016-0.00051-
0.00124-0.00108b
0/18-2/22-1/22-4/21-
20/25-28/28
hpc Rat/M (42)
ME 0-37-75-150-300 Gavage 104-104-104-53 0-26.4-53.6-107.1-101.85b 2/50-3/50-14/50-25/50-36/50 hpc Rat/M (43)
SA 0-4-20-40-200 Diet 104 0-4-20-40-200 3/25-1/25-2/25-2/25-7/25 tum Rat/M (44)
MeIQx 0-4-8-16 Diet 56 0-1.16-2.32-4.64 0/15-0/30-13/29-15/16 hpc Rat/M (45)
TAM 0-5-20-35 Gavage 104-104-87-71 0-5-14-16.31 0/104-6/52-37/52-37/52 hpc Rat/F (46)
TAM 0-11.3-22.6 Gavage 52 0-2.83-5.65 0/18-16/36-24/24 hpc Rat/F (47)
F, female; M, male; hpa, hepatocellular adenoma; hpc, hepatocellular carcinoma; tum, different liver tumour; w, weeks; m, months.
aFor each individual data set, the dose was adjusted to the time of treatment (28), to the duration of the in vivo study and to the lifespan of rats of 104 w (for further
explanations, see text).
bHighest dose was not used when performing the BMD analysis.
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Table III. Name of compound, sex, species, reference, P-values, log-likelihood, AIC, degrees of freedom (d.f.) and BMD10 obtained with the different models
using the EPA BMD software version 2.1.1 for the DNA-reactive compounds selected and the extrapolated amount of DNA adducts formed for each individual
BMD10 based on the regressions in Figure 1
Model P-value Log likelihood AIC d.f. BMD10
a Number adducts in 108 nt
2-AAF, male rat (29,41)
Full 16.85
Reduced 76.08 3
Gamma 1 16.85 37.70 2 0.32 7561
Logistic 0.60 17.67 39.34 2 0.45 10729
Log-logistic 0.99 16.86 37.73 2 0.32 7585
Log-probit 0.999 16.85 37.70 2 0.32 7585
Multistage 1 16.85 37.70 2 0.31 7537
Multistage cancer 1 16.85 37.70 2 0.31 7537
Weibull 1 16.85 37.70 2 0.31 7537
Probit 0.68 17.45 38.90 2 0.41 9937
Quantal linear 0.067 21.22 44.44 3
AfB1, male rat (30,42)
Full 33.51
Reduced 63.98 4
Gamma 0.25 35.28 76.57 2 0.00043 17.56
Logistic 0.41 35.15 74.31 3 0.00039 15.75
Log-logistic 0.25 35.28 76.56 3 0.00043 17.67
Log-probit 0.41 34.75 75.49 2 0.00045 18.37
Multistage 0.30 35.49 74.98 3 0.00033 13.49
Multistage cancer 0.30 35.49 74.98 3 0.00033 13.49
Weibull 0.24 35.27 76.55 2 0.00042 16.84
Probit 0.35 35.19 74.37 3 0.00035 14.17
Quantal linear 0.085 37.76 77.51 4
MeIQx, male rat (33,45)
Full 23.69
Reduced 55.79 3
Gamma 0.42 24.79 53.59 2 1.59 721.6
Logistic 0.06 26.44 56.87 2
Log-logistic 0.57 24.44 52.87 2 1.65 748.7
Log-probit 0.65 24.27 52.54 2 1.62 736.2
Multistage 0.17 28.04 58.07 3 1.04 473.7
Multistage cancer 0.17 28.04 58.07 3 1.04 473.7
Weibull 0.19 26.09 56.17 2 1.44 651.9
Probit 0.09 26.45 56.91 2
Quantal linear 0.0019 35.40 72.81 3
ME, male rat (31,43)
Full 84.01
Reduced 106.63 3
Gamma 0.24 84.72 175.43 1 35.39 35.10
Logistic 0.21 85.58 175.14 2 40.10 39.76
Log-logistic 0.27 84.65 175.30 1 35.16 34.87
Log-probit 0.36 84.44 174.87 1 35.84 35.54
Multistage 0.16 84.99 175.98 1 35.70 35.41
Multistage cancer 0.16 84.99 175.98 1 35.70 35.41
Weibull 0.18 84.97 175.94 1 34.20 33.92
Probit 0.27 85.31 174.62 2 37.19 36.88
Quantal linear 0.09 86.80 177.60 2
SA, male rat (32,44)
Full 42.13
Reduced 45.86 4
Gamma 0.58 42.70 91.40 2 158.80 649.5
Logistic 0.71 42.79 89.58 3 117.31 479.8
Log-logistic 0.58 44.70 95.40 2 167.94 686.8
Log-probit 0.58 42.70 91.40 2 153.51 627.8
Multistage 0.77 42.71 89.42 3 130.69 534.5
Multistage cancer 0.77 42.71 89.42 3 130.69 534.5
Weibull 0.58 42.70 91.40 2 169.11 691.6
Probit 0.70 42.81 89.62 3 112.66 460.8
Quantal linear 0.62 42.97 89.94 3 91.20 372.9
TAM, female rat (34,46)
Full 81.07
Reduced 160.48 3
Gamma 0.55 81.67 167.35 2 4.56 69.31
Logistic 0.055 84.77 173.45 2
Log-logistic 0.65 81.57 167.02 2 4.60 69.92
Log-probit 0.65 81.50 167.01 2 4.66 70.83
Multistage 0.67 81.86 165.72 2 4.44 67.49
Multistage cancer 0.67 81.86 165.72 2 4.44 67.49
Weibull 0.46 81.86 167.72 2 4.39 66.73
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of magnitude. The data also lead to the conclusion that for all
six DNA-reactive carcinogens, the actual level of DNA adducts
formed at the BMD10 do not vary by more than 3 orders of
magnitude. This may be related to the fact that genotoxic
electrophiles can react at different sites within the DNA,
resulting in the formation of different types of adducts.
Together, these results quantitatively support the conclusion
that all individual DNA-reactive selected compounds 2-AAF,
AfB1, MeIQx, TAM, SA and ME give rise to DNA adducts
with a 10- to 100-fold different potential to result in mutations
and ultimately cancer.
Species differences in 2-AAF DNA adduct formation
Figure 4 presents the dose-dependent DNA adduct formation
measured in liver of mice chronically exposed to 2-AAF
(49). In addition, literature data on tumour formation in the
liver of mice dosed with 2AAF (50) were used to determine
the BMD10 value (Figure 4). For both studies, the feed
concentrations in p.p.m. were converted to the following
dose range: 0, 0.65, 1.3, 1.95, 3.9, 5.85, 7.8, 9.75, 13 and
19.5 mg/kg bw/day. DNA adduct levels at 1 mg/kg bw/day,
the average BMD10 and the average DNA adduct formation
at the BMD10 are displayed in Table IV. When comparing
the average DNA adduct levels at the average BMD10, it was
found that at the BMD10, DNA adduct formation in rat was
8-fold greater than in mouse. Previous data derived for DNA
adduct levels in rats and mice at the TD50 value were in line
with this result (51).
Endogenous DNA adduct levels
Endogenous or background DNA damage occurs constantly in
all human and animal tissues, induced, for instance, through
oxidative stress, the formation of radicals or reactive, alkylating
metabolites. The targets of these ‘stressors’ are numerous and
can be the deoxyribose-phosphodiester backbone, the glyco-
sidic linkages connecting the nucleobases to the DNA
backbone or the nucleobases itself, leading to a plethora of
different possible primary and secondary modifications (52)
that can have profound biological consequences. For the
purpose of this manuscript, we use the term ‘background’ or
‘endogenous DNA adduct’ for measurable specific covalent
modifications of the nucleobases (including oxidatively
damaged nucleobases) in order to define a background level
for comparison with exogenous carcinogen-specific adduct
formation that principally attack similar atoms of the
nucleobases. Reports in the literature on endogenous levels
of DNA adducts are varied and address both animal and
human tissues. Historically, difficulties were encountered
concerning the performance of analytical methods. For
instance, the determination of oxidatively damaged guanine
Table III. Continued
Model P-value Log likelihood AIC d.f. BMD10
a Number adducts in 108 nt
Probit 0.10 83.83 171.66 2 4.56 69.31
Quantal linear 0.018 86.87 175.74 3
TAM, female rat (34,47)
Full 24.73
Reduced 54.04 2
Gamma 0.99 24.76 51.51 2 2.12 32.22
Logistic 0.99 2473 53.46 2 2.54 38.61
Log-logistic 0.99 2473 51.46 2 2.54 38.61
Log-probit 0.99 35.70 53.46 1 2.47 37.54
Multistage 0.33 26.47 54.93 2 1.07 16.26
Multistage cancer 0.33 26.47 54.93 2 1.07 16.26
Weibull 0.99 24.73 53.46 1 1.98 30.10
Probit 0.99 24.73 53.46 1 2.27 34.50
Quantal linear 0.002 54.04 63.39 2
TAM, female rat (35,46)
Full 81.07
Reduced 160.48 3
Gamma 0.55 81.6 167.35 2 4.56 230.5
Logistic 0.055 84.77 173.45 2
Log-logistic 0.65 81.57 167.02 2 4.60
Log-probit 0.65 81.50 167.01 2 4.66 232.5
Multistage 0.67 81.86 165.72 2 4.44 235.5
Multistage cancer 0.67 81.86 165.72 2 4.44 224.4
Weibull 0.46 81.86 167.72 2 4.39 224.4
Probit 0.10 83.83 171.66 2 4.56 221.5
Quantal linear 0.018 86.87 175.74 3
TAM, female rat (35,47)
Full 24.73
Reduced 54.04 2
Gamma 0.99 24.76 51.51 2 2.12 107.1
Logistic 0.99 24.73 53.46 2 2.54 128.4
Log-logistic 0.99 24.73 51.46 2 2.54 125.4
Log-probit 0.99 35.70 53.46 1 2.47 124.8
Multistage 0.33 26.47 54.93 2 1.07 54.08
Multistage cancer 0.33 26.47 54.93 2 1.07 54.08
Weibull 0.99 24.73 53.46 1 1.98 100.1
Probit 0.99 24.73 53.46 1 2.27 114.7
Quantal linear 0.002 54.04 63.39 2
aThe BMD10 are expressed as milligrams per kilogram body weight per day (mg/kg bw/day).
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(8-oxo-7,8-dihydroguanine, 8-oxo-dG) led to important over-
estimations due to artifactual DNA oxidation during the
analytical sample workup (53–56). Due to the heterogeneity
of adducts and available methods and the fact that most recent
comprehensive reviews focus on human endogenous DNA
adducts (3,57), detailed knowledge on endogenous DNA
adduct formation in rat tissues is actually limited. Represen-
tative data on levels of the most studied endogenous adducts, in
human and rat liver, were extracted from the literature and are
summarised in Table V. Though not being exhaustive, the list
provides a reasonable indication of the overall endogenous
adduct levels. It is obvious that, even within the same species
and organ, levels of a specific adduct can easily vary by .1
order of magnitude (e.g. in rats: 8-oxo-dG, 23-480/108 nt and
M1G, 1-52/108 nt). The results presented in Table V revealed
that oxidative damage usually exceeds other endogenous DNA
adducts induced by alkylation or lipid oxidation which is in
agreement with previous reviews (3,57,70). In addition,
endogenous DNA adduct levels tend to be somewhat higher
in humans than in rats, probably due to non-controllable and
lifestyle factors such as unknown dietary and environmental
sources of exposure to alkylating agents, smoking or oxidative/
metabolic stress as compared to the controlled housing
conditions of laboratory animals. In general, it has been
reported that endogenous DNA adduct levels are present in 100
adducts in 108 nt (6), and additionally, the level was reported
by Farmer (71,72) to be generally 10–100 adducts in 108 nt for
low molecular weight alkylating electrophiles. Based on these
data, in the present manuscript the background of the alkylating
endogenous DNA adduct level was defined at 10–100 adducts
in 108 nt and used as the relevant background level for
endogenous DNA adduct formation. This level of endogenous
DNA adduct formation was also previously used to compare
estragole DNA adduct formation predicted by our physiolog-
ically based biodynamic model for DNA adduct formation in
male rat liver after exposure to estragole (73).
Fig. 2. Illustration of the dose–response curves for DNA adduct formation with the range of accepted BMD10 values (dashed lines) derived from in vivo data on liver
tumour incidence, representing the data for male rats treated with: (A) 2-AAF, (B) AfB1, (C) MeIQx, (E) SA, (F) ME and female rats treated with (D) TAM (34,35).
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In a next step, the DNA adduct levels calculated at the
BMD10 (Table III) were compared to reported endogenous
levels of DNA adduct formation (Table V). The value of 10–
100 adducts in 108 nt was included resulting in Figure 3, which
allows comparison of the DNA adduct levels at the BMD10 to
the endogenous DNA adduct levels in rat liver. When
comparing the levels between genotoxic compounds, it appears
that the number of DNA adducts in 108 nt formed at the highest
BMD10, for 2-AAF, MeIQx, SA, TAM were 100-, 7.5-, 6.9-,
2.3-fold higher than the highest value set for the endogenous
DNA adduct levels (100 adducts in 108 nt). For AfB1 and ME,
the predicted levels of DNA adduct formation at the BMD10
was within the background level of 10–100 adducts 108 nt. In
the specific case of TAM, the amount of DNA adducts at the
BMD10 resulted in four different sets of values (Figure 3) since
two studies on DNA adduct formation and two tumour
incidence studies were available for this compound. Two data
sets falling within the endogenous background level, while one
data set was above the endogenous background and the fourth
data set was partially above the background level. When the
TAM adducts calculated at the BMD10 were based on data
generated using different analytical methods (35), the values
obtained did not vary by more than a factor of 2 (not shown),
which is much less than the differences observed between
different animal studies.
Discussion
In the present manuscript, a comparison was made between in
vivo DNA adduct formation, cancer induction and background
DNA adduct formation using a series of selected DNA-reactive
carcinogens: 2-AAF, AfB1, ME, SA, MeIQx and TAM, as
model compounds. The aim of this study was to use a uniform
data set on DNA-reactive genotoxic carcinogens that induce,
with or without metabolic activation, DNA adducts which can
lead to hepatocellular carcinogenic transformation, in order to
analyse if a correlation between the formation of DNA adducts
and cancer incidences in the target organ can be obtained.
A decade ago, Otteneder and Lutz (74), making a similar
effort, indicated that there was a need of more data on DNA
adduct levels in target tissues of rodents and human. After
more than 10 years, little progress has been made since
a thorough literature search revealed only six DNA-reactive
carcinogens for which in addition to tumour data also data on
in vivo DNA adduct formation in the same target tissue, species
Fig. 3. Levels of DNA adduct formation at the BMD10 for liver tumour formation by the six model compounds as related to endogenous DNA adduct levels (10–100
adducts in 108 nt, grey shadow) in liver. The individual data points represent the outcome of each individual mathematical model for male rats treated with: 2-AAF,
AfB1, MeIQx, SA, ME and female rats treated with TAM and male mice treated with 2-AAF.
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Fig. 4. Dose-dependent DNA adduct formation (number of adducts in 108 nt)
in the liver as obtained from in vivo studies in male mice treated with 2-AAF,
giving the following slope [(#adduct 108 nt)/(mg/kg bw/day)]: m 5 156.96,
with the range of accepted BMD10 values derived from mice in vivo data from
liver tumour incidence. Inserts are log-log plots of doses and DNA adduct
levels.
Table IV. Species differences in response to 2-AAF: female mice versus male
rats (29,41)
Model Number
adducts
in 108 nt for
1 mg/kg/bw/day
Average
BMD10
Average
number
adducts in 108
nt at the BMD10
Mice 157.0 6.07 953.0
Rat 24002 0.343 8250
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and gender were available. Otteneder and Lutz (74) used
carcinogen-DNA adduct levels associated with a 50% tumour
incidence, using data from both mice and rats, males and
females. In the present manuscript, we used data on DNA
adducts and cancer incidences exclusively for rat, within the
same gender, and dose responses for cancer incidences were
modelled using a BMD approach. In addition, data were
compared to endogenous DNA adduct levels. Although for an
individual carcinogen, the tumour response increases when
adduct levels increase, our results demonstrate that when
comparing different carcinogens, no quantitative correlation
exists between the level of DNA adduct formation and
carcinogenicity. Assuming that DNA adducts have a role in
cancer development, the data corroborate that the different
DNA adducts have different mutagenic and carcinogenic
potential. The evaluation of DNA adduct data represents
a particular difficulty, especially in risk assessment (8). Jarabek
et al. (8) defined mutagenic efficiency to be: ‘the probability
that a DNA adduct or an adduct load converts a normal cell to
a viable cell containing a heritable alteration in the DNA (i.e.
a mutation)’; the efficiency of conversion of a promutagenic
DNA adduct to a mutation depends on a wide range of factors
including the type and chirality of the adduct; the cell-, tissue-
or organ-specific DNA repair and metabolism; the local DNA
sequence context of the adduct; the lability/stability of the
adduct; the extent of disruption induced in the helix structure;
the capacity of the affected cell to replicate to form a clone and
other cellular processes such as the frequency of cell
replication. All these parameters must be considered when
dealing with DNA adducts in risk assessment. Furthermore, it
is important to underline that unlike the rodent 2-year cancer
bioassay, that is conducted according to guideline protocols
since considerable time, with agreed procedures as to adjust
doses for exposure and treatment duration in order to allow
comparability between studies and compounds, analyses of in
vivo DNA adduct formation have variable study designs, are
usually done for very specific purposes, with particular dosing
regimens and duration depending on the question asked.
Therefore, we corrected for these diverting factors as much as
possible.
Thus, various DNA-reactive carcinogens for which data on
in vivo DNA adduct formation were available, such as for
example dimethylnitrosamine, 2-amino-3-methylimidazo[4,5-
f]quinolone (IQ) and 2,4-diaminotoluene, which were used in
Table V. Quantitative information on endogenous DNA adduct levels limited to liver of humans and rats
Adduct Affected nucleo-base
position
Quantity/106 nta Method Source (h, human; r, rat)
(no. of samples)
Reference
Oxidation
8-oxo-dG C8 0.51 HPLC/ECb r (?) (58)
8-oxo-dG C8 0.84–1.14 HPLCb r (32) (55)
8-oxo-dG C8 1.8–4.8c LC-MS/MS r (3) (59)
8-oxo-dA C8 0.23–0.34c LC-MS/MS r (3) (59)
Lipid peroxidation
M1G N1 0.5–1.1 GC–MS h (6) (60)
M1G N1 0.14 P32/HPLC h (?) (3)
M1G N1 0.9 GC/EC h (?) (3)
M1G N1 0.01 NCI/MS r (4) (61)
M1G N1 0.52 LC-MS/MS r (6) (61)
7-HEG N7 3.0 GC/ECNCI MS h (9) (60)
7-HEG N7 0.06–0.09 GC-HRMS r (?) (62)
7-HEG N7 0.29 32P-pl h (?) (63)
7-HEG N7 0.013 32P-pl r (3) (64,65)
7-HEG N7 0.025 LC-MS/MS r(12) (64,65)
7-CEG N7 0.05 LC-MS/MS h (24) (66)
7-EtG N7 0.0084 LC-MS h (25) (63)
Cyclic adducts
eG N2,C3 0.02 LC-MS h (1) (60)
eG N2,C3 0.012 IA-GC/HRMS r (8) (67)
eG N2,C3 0.007 IA-GC/HRMS r (7) (67)
edA C1,N6 0.001–0.002 IA 32P-pl r (3) (68)
edA C1,N6 0.006 IA 32P-pl h (10) (69)
edC C3,N4 0.006–0.008 IA 32P-pl r (3) (68)
edC C3,N4 0.007 IA 32P-pl h (10) (69)
HNE-dG C1,N2 0.0006–0.0018 HPLC/P32-pl h (?) (3)
Acr-dG C1,N2 0.06–0.4 HPLC/P32-pl h (?) (3)
Alkylation
7-MG N7 0.21–0.25 32P-pl r (?) (62)
7-MG N7 0.27 32P-pl r (?) (62)
O6-MeG O6 0.022–0.13 PREPI h (?) (3)
O4-MeT O4 0.003–0.42 PREPI h (?) (3)
O4-EtT O4 0.015–4.24 PREPI h (?) (3)
Abasic sites – 8–9 ASB h (?) (3)
IA, immunoaffinity purification; PREPI, 32P-postlabelling (32P-pl) followed by high-performance liquid chromatography and immunoprecipitation; ASB,
combination of aldehyde-reactive probe and slot blot techniques; HRMS, high-resolution mass spectrometry; HNE, 4-hydroxynonenal; Acr, acrolein; ECNCI,
electron capture negative chemical ionisation;?, number of samples not specified.
aIn part corrected from the number of adducts per normal parent base by using a content of 22% G or C and 28% of A or T in mammalian DNA.
bImproved workup to minimise artifactual formation.
cDepending on extraction procedure (chaotropic extraction or anion exchange, respectively).
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Otteneder and Lutz (74) did not have tumour incidence data
meeting the criteria set in this manuscript. And for many other
DNA-reactive compounds for which long-term carcinogenicity
data are available, data on in vivo DNA adduct formation are
lacking. The selection of the compounds in the present study
was done following the following criteria: (i) available data on
in vivo DNA adduct formation and (ii) available dose–response
data for tumour induction, both in the same target tissue, the
liver, and for the same species, the rat and for the same gender.
In further analysis of the results obtained, it was important to
take into account other critical steps underlined by Otteneder
and Lutz (74) such as: (i) DNA adduct measurement is
a balance between formation of the adduct, repair, cell death
and dilution of the adduct formed by DNA replication (ii) the
period of treatment should be long enough to achieve a steady
state and (iii) the relationship between DNA adducts detected
and tumour incidence may be influenced by the time of
sacrifice of the animal after administration of the compound.
DNA adduct data obtained from literature revealed that all the
experimental data sets, although limited, appear compatible
with linearity to the origin, a finding that is in line with the
current understanding of DNA-adduct dose–response behav-
iour (75). DNA adduct levels detected can be expected to
reflect a balance between DNA adduct formation and DNA
repair, cell death and dilution of the adduct formed by DNA
replication (76).
The data obtained point at a different potency for each
individual compound to result in DNA adduct formation, with
AfB1 and 2-AAF being at least 2–3 orders of magnitude more
effective in forming DNA adducts than MeIQx and SA and
even 4 orders of magnitude more effective than ME and TAM.
Such differences can be expected to result for example from
differences in the reactivity of the DNA-reactive intermediate
formed, in the relative percentage of the dose that is actually
converted to the DNA-reactive metabolite and/or in the
stability of the DNA adduct formed. DNA adducts are
produced when electrophilic compounds covalently bind to
a base of the DNA structure, forming different types of DNA
adducts (6). DNA adducts vary greatly in their half-lives,
which depends on their chemical stability, their repair by DNA
repair processes and/or their elimination through apoptosis and/
or cell death. The site of formation of the electrophilic
metabolite, combined with its chemical stability, influences the
cellular and tissue distribution of DNA adducts. For instance,
highly unstable electrophiles do not persist long enough to
form adducts in tissues distant to the site of metabolic
activation (6). On the other hand, relatively stable metabolites
can circulate in the blood and form DNA adducts in many
tissues (6). Furthermore, tissue-specific possibilities for DNA
repair can greatly affect the amount of DNA adducts present in
a tissue. In a repair-proficient tissue, the amount of DNA
adduct rapidly decreases but if the tissue is deficient in repair
mechanisms, then the amount of DNA adducts remains
unaffected (6).
Furthermore, as outlined by Otteneder and Lutz (74), it is
important to note that, when comparing the relative potency of
the different model compounds to form DNA adducts, the
period of treatment underlying the data for which the
comparison is made should be long enough to achieve a steady
state. Steady-state levels are reached when the number of DNA
adducts formed are equal to the number that are destroyed and
repaired and this may be achieved either after a single exposure
or only after repeated exposure to a DNA-reactive compound,
the latter leading to an increase in DNA adduct formation over
time. For highly unstable or rapidly repaired DNA adducts
(such as N-3 methyladenine or N-7 oestrogen adducts on
adenine), steady state may be reached as quickly as following
the first daily dose (6). However, in other cases (i.e. N7-
alkylguanine adducts), a steady state may only be achieved in
7–10 days, whereas more persistent adducts (such as O4-ethyl
thymidine) can accumulate over a period of 4 weeks (6).
In the present paper, we have normalised the data either only
with respect to the dose or with respect to both the dose and
duration of exposure. Some data are available that could
provide at least some insight into the actual influence of dose
and duration of exposure on the normalised levels of DNA
adduct formed. For example, for SA, DNA adduct levels were
measured after one injection and after five repeated daily
injections. The DNA adduct levels at the same dose (1 mg/kg
bw/day) for the single exposure, amounted to 1.40 108 nt/day,
whereas it amounted to a normalised value of 0.8 108 nt/day
after five daily injections, indicating that the repeated daily
exposure gave a somewhat lower amount of DNA adducts
formed when normalised to 1 day. Similarly, for MeIQx, DNA
adduct measurements obtained after 1- and 12-week adminis-
tration of the same dose level revealed that after normalisation,
the longer treatment period (12 weeks) resulted in a lower
number of DNA adducts amounting to 1.89 108 nt/day than the
1-week exposure period, which resulted in 8.8 108 nt/day.
Clearly, however, these differences due to varying duration of
the dosing remain within an order of magnitude and are thus
smaller than the differences in the levels of DNA adduct
formation at a dose of 1 mg/kg bw/day obtained for the model
compounds of the present study. Furthermore, the amount of
DNA adducts detected may be influenced by the time of
sacrifice of the animal after administration of the compound
(77). Therefore, it could be important to take into account the
time period between the last treatment and sacrifice when
analysing DNA adduct levels in vivo. In the studies discussed
in the present manuscript, two studies reported that the period
between dosing and sampling was 24 h (29,32), whereas for the
remaining studies, this time was not specified, hampering
further evaluation of this possible factor of influence. In the
special case of 2AAF, complete data sets (DNA adducts and
tumour incidence in liver) were available for both rats and
mice. Analysis of these data revealed that at the BMD10, the
levels of DNA adduct formation in rat appeared to be 8-fold
higher than the levels in mouse. This suggests that, for this
compound, there is a species-dependent difference in sensitiv-
ity with rats requiring higher levels of DNA adduct formation
for a similar level of tumour formation, and the difference
between species (rat versus mice) indicating that mice are more
sensitive to this compound than rats.
The present manuscript also focuses on the possible role of
DNA adduct formation in the MOA of the different DNA-
reactive carcinogens and the endogenous DNA adduct levels.
With respect to these MOAs, it has been reported for example
that DNA adduct formation by AfB1 produces 8,9-dihydro-8-
(N7-guanyl)-9-hydroxyaflatoxin B1 (AfB1-N7-Gua), which is
converted naturally to two secondary lesions, an apurinic site
and an AFB1-formamidopyrimidine (AfB1-FAPY) adduct.
AfB1-FAPY is detected at near maximal levels in rat DNA
days to weeks after AfB1 exposure, underscoring its high
persistence in vivo (78). Furthermore, the DNA adduct
formation by AfB1 does not occur randomly within the DNA
but rather at so-called mutational hot spots causing mutations
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with high frequency in the p53 gene (79). It has been shown in
humans that AfB1 acts preferably on Codon 249 and 250 of the
p53 gene, resulting in AGG to AGT and CCC to ACC
transversions with a relative mutation frequency of 15  106
(79). The putative hot spot in humans, Codon 249, corresponds
to Codon 243 in the rat gene, which is located in Exon 6.
Results suggested that mutation at the site corresponding to the
hot spot Codon 243 in the rat gene is rare (80). Given,
however, that the occurrence of these mutational hot spots for
AfB1 may not occur in rats (80), the first explanation pointing
at high persistence of the AfB1 DNA adducts may provide an
alternative explanation for their high mutagenic and carcino-
genic potential compared to that of endogenous DNA
modifications. Reduction of aflatoxin-DNA adduct levels by
chemopreventive agents could reduce the number of foci
present and could be used as predictive of cancer preventive
efficacy (81,82). For TAM, mutations are found in the liver,
including predominantly GC/TA transversions (83) and
Liapis et al. (84) predicted, using an in silico model, GC/TA
mutational hot spots for TAM at Codons 244 and 273 of p53.
Among the 393 codons of the human p53 gene, 222 are the
targets of 698 different mutational events (85). By reacting at
different spots, the ability of different genotoxic carcinogens to
result in tumour formation can be expected to differ. Given this
situation, it is of interest to note that the actual levels of DNA
adduct formation observed for the different DNA-reactive
carcinogens at their BMD10 differ by only 1–2 orders of
magnitude.
The general background level of DNA adducts was defined
at 10–100 adducts in 108 nt (5,70,71,76). Based on the data
obtained, a comparison of the level of DNA adducts
calculated to be observed at a dose level amounting to the
BMD10 for tumour formation by the model carcinogens
selected for the present study, to this endogenous DNA
adduct levels in rat liver tissue could be made (Figure 3). For
2-AAF, 2-MeIQx and SA, DNA adduct formation at the
BMD10 was above background levels for DNA adduct
formation and may thus contribute to their MOA. The levels
of DNA adduct formation expected at the BMD10 were
actually below or close to the background DNA adduct level
set a 100 adduct in 108 nt for (i) the study with female rats
treated with TAM, (ii) the study with ME in male rats and (iii)
the study with male rats treated with AfB1. Theoretically, this
observation of DNA adduct formation at the BMD10 at levels
that are below the background levels of DNA adduct
formation might reflect that either the DNA adducts formed
are far more mutagenic and carcinogenic than the type of
lesions included in the background levels or it might imply
that the mechanism underlying the tumour induction is not
related to the DNA adduct formation but rather due to another
mechanism of action such as for example cytotoxicity. Given
the present proposals for the MOA of ME, TAM and AfB1,
one might conclude that the first explanation holds for AfB1
pointing at formation of DNA adducts that are more
mutagenic and carcinogenic than background type DNA
lesions. The AfB1 mutation at high frequency in a hot spot in
the p53 tumour suppressor gene (79) and/or leading to DNA
adducts with relatively high persistence (86) supports this
hypothesis. An efficacy of at least 1 order of magnitude higher
than the efficacy of background DNA lesions to result in
tumour induction would already explain that the level of
adduct formation by AfB1 can result in tumour incidences
above background level. Poirier and Beland (87) reported that
the high carcinogenic potency of AfB1 may result in tumour
formation at concentrations that do not saturate metabolic
pathways, stimulate cell proliferation or induce extensive
toxicity. For ME, literature data point at a possible role for
liver toxicity in the mechanism underlying tumour formation
(88) and the results of the present analysis may corroborate
involvement of another mechanism than merely DNA adduct
formation in the MOA of this DNA-reactive carcinogen.
Finally, for the specific case of TAM, there are still several
options for the MOA of this genotoxic carcinogen. Formation
of DNA adducts at mutational hot spots in the p53 tumour
suppressor gene as suggested by Liapis et al. (84) may
support formation of DNA adducts with higher potency for
tumour induction than background DNA adducts, whereas on
the other hand, involvement of TAM or its metabolite 4-
hydroxytamoxifen as a partial oestrogen receptor alpha
agonist (84) may point at a MOA including increased cell
proliferation and tumour formation induced by oestrogen
receptor alpha agonist activity, representing a MOA other
than the association of hepatic tumors with accumulation of
DNA adducts in the liver (47). Oestrogen receptor alpha
activation may indeed play a role in hepatic tumour formation
in rodents (46).
Overall, the results of the present paper reveal that for some
DNA-reactive carcinogens, the level of DNA adduct formation
at the BMD10 for tumour formation does not significantly
exceed endogenous DNA adduct levels, pointing at either the
formation of DNA adducts that are more effective in inducing
carcinogenesis than background DNA adducts or corroborating
the involvement of other MOAs than DNA adduct formation
underlying their carcinogenicity.
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